WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors. SNV1521 is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.
The Phase I trial, which is being led by Timothy Yap, M.D., Ph.D., professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, is designed to assess proof-of-concept with SNV1521 as an oral monotherapy in a dose escalation and preliminary efficacy expansion study. PARP inhibition is clinically validated for homologous recombination deficiency (HRD, a molecular biomarker) driven cancers; however, the safety profile of first generation PARP1 agents limits the potential of the class, particularly in combination with chemotherapy or other novel agents. In preclinical models, selective PARP1 targeting has been shown to improve both the efficacy and safety of the class.
“We believe that a highly potent and selective PARP1 inhibitor - such as SNV1521 - has the potential for both improved efficacy and enhanced safety due to its excellent physicochemical properties,” said Kevin O’Hayer, M.D., Ph.D., Senior Vice President, Head of Clinical Development at Synnovation. “Dosing of the first patient in the SNV1521 Phase I trial is a key milestone as Synnovation transitions from a preclinical to clinical stage biotech company. We are excited to collaborate with Dr. Yap and the rest of our SNV1521 study investigators on this program.”
About Synnovation Therapeutics
Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets. The company was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics. Synnovation’s pipeline is built around highly validated precision oncologic targets where greater potency and selectivity and optimized pharmaceutical properties have the potential to address liabilities in existing standards of care, and meaningfully improve patient outcomes. The company’s lead program, SNV1521, is a potentially best-in-class potent, selective and CNS penetrant PARP1 inhibitor is in a Phase I study. For more information, please visit www.synnovationtx.com.
